Quoin Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
The notification from Nasdaq confirms that for the last 13 consecutive business days, the closing bid price of the Company's ordinary shares was at or above $1.00 per share. Accordingly, Nasdaq considers the matter closed.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances, such as 'expect,' 'intend,' 'hope,' 'plan,' 'potential,' 'anticipate,' 'look forward,' 'believe,' 'may,' and 'will,' among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to: Quoin's products in development collectively having the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the Company's ability to deliver a safe and effective treatment for Netherton Syndrome; whether the Company's studies successfully generate data that is sufficiently robust and comprehensive to support an NDA filing for QRX003 as an approved treatment for Netherton Syndrome; and other factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and in other filings the Company has made and may make with the SEC in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Quoin Pharmaceuticals Ltd.
Michael Myers, Ph.D., CEO
[email protected]
Investor Relations
PCG Advisory
Jeff Ramson
[email protected]
(646) 863-6341
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Baird Reduces PT on lululemon athletica (LULU) Stock
lululemon athletica inc. (NASDAQ:LULU) is one of the Oversold Fundamentally Strong Stocks to Buy Now. On August 11, Baird reduced the price objective on the company's stock to $260 from $340, keeping an 'Outperform' rating, as reported by The Fly. The firm updated the model after the recent selloff. In Q1 2025, lululemon athletica inc. (NASDAQ:LULU) saw growth throughout channels, categories, and markets, which include the US, reflecting the continued strength and agility of its business model. A store employee in an athletic apparel store restocking merchandise. lululemon athletica inc. (NASDAQ:LULU) added 3 net new company-operated stores during Q1 2025, ending with 770 stores. The company's gross margin came in at 58.3% in Q1 2025 as compared to 57.7% in Q1 2024. The rise was mainly because of a net increase in product margin of 110 bps, comprising a net increase of 130 bps due to reduced product costs and increased average unit retail, and lower damages, partially offset by elevated freight costs, and an unfavorable impact of foreign currency exchange rates of 20 bps. Diamond Hill Capital, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Other bottom contributors in Q1 included Lululemon athletica inc. (NASDAQ:LULU), General Motors and Capital One. Shares of athletic apparel manufacturer lululemon were pressured amid ongoing concerns about potential brand saturation in the Americas, its largest market. However, we believe the company is operating well and is positioned to improve US sales performance while continuing to grow international sales — factors that make the current valuation compelling, in our view.' While we acknowledge the potential of LULU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Citi Raised the Firm's PT on Expedia Group (EXPE), Kept a Neutral Rating
Expedia Group, Inc. (NASDAQ:EXPE) is one of the Undervalued Cyclical Stocks to Buy According to Hedge Funds. On August 13, Citi raised the firm's price target on Expedia Group, Inc. (NASDAQ:EXPE) from $177 to $206, while keeping a Neutral rating on the stock. The improved sentiment follows the company's strong second-quarter results for 2025. The company delivered $3.79 billion, up 6.41% year-over-year and ahead of estimates by $76.04 million. The EPS of $4.24 also beat expectations by $0.11. The analyst noted Expedia Group, Inc. (NASDAQ:EXPE) delivered better than expected results with gross bookings 2% above consensus, driven by a 7% increase in room nights. The firm also noted an improved demand from the US in July, which benefited the company. People interacting with a travel website, searching for the perfect destination. Expedia Group, Inc. (NASDAQ:EXPE) is an online travel company offering a wide range of travel services through consumer brands like Vrbo, and others. While we acknowledge the potential of EXPE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
an hour ago
- Yahoo
Citi Raised the Firm's PT on JD.com (JD), Kept a Buy Rating
Inc. (NASDAQ:JD) is one of the Undervalued Cyclical Stocks to Buy According to Hedge Funds. On August 14, Citi analyst Alicia Yap raised the firm's price target on Inc. (NASDAQ:JD) from $42 to $44, while maintaining a Buy rating on the stock. The improved sentiment for the company follows its announcement of robust fiscal second-quarter 2025 results. Inc. (NASDAQ:JD) delivered RMB356.7 billion in revenue for the quarter, up 22.4% year-over-year, exceeding Wall Street estimates. Management noted that its Retail segment showed solid performance with revenue growing 20.6% and operating margins improving 4.5%. This was its highest margin in any promotional quarter. A wide and imposing view of a supply chain distribution center, illustrating the company's technology capabilities. Inc. (NASDAQ:JD) is an e-commerce company operating through its retail mobile apps and website, offering online retail and marketplace services. While we acknowledge the potential of JD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
